AI Article Synopsis
- A patient with relapsed follicular lymphoma developed secondary acute myeloid leukemia 15 months after receiving radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, marking the fifth known case of this occurrence.
- Researchers examined existing literature to explore the potential link between RIT and the onset of secondary myelodysplastic syndromes or acute myeloid leukemia.
- This case highlights the need for ongoing investigation into the long-term effects of RIT on patients and the risks of developing secondary cancers.
Article Abstract
We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between RIT and secondary myelodysplastic syndromes/acute myeloid leukaemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hon.849 | DOI Listing |
Publication Analysis
Top Keywords
myeloid leukaemia
12
acute myeloid
8
90y-ibritumomab tiuxetan
8
follicular lymphoma
8
leukaemia treatment
4
treatment 90y-ibritumomab
4
tiuxetan follicular
4
lymphoma report
4
report patient
4
patient relapsed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!